Group 1 - The core viewpoint of the articles highlights the performance and valuation of Xinmai Medical, which closed at 101.93 yuan with a PE ratio of 28.08, significantly lower than the industry average of 53.52 [1][3] - Xinmai Medical specializes in the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels, with key products including stent systems and balloon catheters [2] - The company has received several accolades, including the Shanghai Government Quality Gold Award and recognition as one of the top 30 companies in the Sci-Tech Innovation Board [2] Group 2 - As of the first quarter of 2025, Xinmai Medical reported a revenue of 3.32 billion yuan, a year-on-year decrease of 7.23%, and a net profit of 1.30 billion yuan, down 29.66%, with a gross margin of 69.61% [2] - The company ranks 57th in terms of PE ratio within its industry, indicating a relatively lower valuation compared to peers [1][3] - Four institutions hold shares in Xinmai Medical, with a total of 89,200 shares valued at 0.08 billion yuan [1]

Company Overview - Shanghai MicroPort CardioFlow Medtech Co., Ltd. specializes in the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels [2] - The main products include thoracic aortic stent graft systems, abdominal aortic stent graft systems, intraoperative stents, balloon catheters, and stents [2] Recent Performance - As of the first quarter of 2025, the company reported revenue of 332 million yuan, a year-on-year decrease of 7.23%, and a net profit of 130 million yuan, down 29.66% year-on-year [2] - The sales gross margin stands at 69.61% [2] Market Position - The company's stock closed at 95.92 yuan, with a rolling price-to-earnings (PE) ratio of 26.42, marking a new low in 67 days [1] - The total market capitalization is 11.823 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 52.06, with a median of 37.22, placing the company at the 57th position in the industry ranking [1][3] Institutional Holdings - As of the first quarter of 2025, 11 institutions hold shares in the company, including 5 funds, 4 others, 1 brokerage, and 1 social security fund, with a total holding of 56.5791 million shares valued at 5.098 billion yuan [1]

文/梧桐兄弟 近期，心脉医疗（688016）披露《关于收到税务事项通知书需补缴税款的公告》，上海微创心脉医疗科技（集团）股份有限公司（以下简称"公司"）收到国家税 务总局上海市浦东新区税务局第二税务所（以下简称"浦东新区税务局第二税务所"）发来的《税务事项通知书》（沪税浦二通〔2024〕1186号）。 据公告， 1、 2024年8月14日 ，上海市高新技术企业认定指导小组发布《关于2024年上海市第二批取消高新技术企业资格的公告》（沪高企认指〔2024〕005号，以下简 称"取消高企资格公告"）， 因公司累计两年（2021年、2022年）未填报企业年度发展情况报表被取消高新技术企业资格，取消起始年度为2023年。 2、2024年11月29日，浦东新区税务局第二税务所依据取消高企资格公告向公司发出《税务事项通知书》， 因公司被取消高新技术企业资格，税务机关按规定追缴 公司不符合认定条件年度起（即2023年）已享受的税收优惠，并要求缴纳滞纳金。 3、根据《中华人民共和国税收征收管理法》第三十二条等规定， 经公司初步测算，需补缴的税款及滞纳金合计约为人民币6,000-7,000万元，对净利润的影响预计 占公司最近一 ...